PCA Administration in Prosthetic Joint Infection

Launched by DR. DEAN REEVES CLINIC · Sep 10, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how a dietary supplement called protocatechuic acid (PCA) might influence health markers in patients who need surgery again due to an infection in their knee joint replacement. The goal is to see if PCA can help improve the health of those affected by this type of infection.

To be eligible for the trial, participants should be adults aged 65 to 74 who have experienced symptoms of infection, like redness, swelling, pain, or fever, for at least three weeks after their knee replacement surgery. They will also need to have a specific level of white blood cells in their joint fluid indicating an infection. If you choose to take part, you will need to agree to have a blood sample taken three months into the study. The trial is not yet recruiting participants, but it’s an important step toward understanding new ways to manage infections in knee replacements.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 3 weeks or more after total knee arthroplasty
• • One or more symptoms of infection, including redness, swelling, pain, increasing range of motion loss, fever, nausea, and loss of appetite.
• • WBC count of aspirate \>50,000 cells per μL
• Exclusion Criteria:
• • Not willing to undergo blood draw at 3 months.